Addiction ProfessionalNew Opioid Overdose Reversal Nasal Spray Receives FDA Approval

Opvee Reverses Remifentail-induced Respiratory Depression Within 5 Minutes

As the opioid crisis continues to evolve, so too does your arsenal of interventions. The FDA’s recent approval of Opvee, a nalmefene-based nasal spray, introduces a new tool for physicians in the fight against opioid overdose.

• The FDA has approved Opvee, a new opioid overdose reversal nasal spray.
• Opvee, developed by Opiant Pharmaceuticals, is designed for patients aged 12 and above.
• The medication contains nalmefene, which reverses remifentail-induced respiratory depression within 2.5 to 5 minutes.
• Opvee is the first nalmefene hydrochloride nasal spray approved by the FDA.
• Some practitioners express concerns about Opvee’s longer acting period and the potential for severe withdrawal symptoms.
• The FDA granted Opiant’s application for Opvee a priority review designation.
• Development of Opvee was supported by up to $18.2 million in funding from BARDA and NIDA.